2,022
Participants
Start Date
August 5, 2009
Primary Completion Date
January 20, 2014
Study Completion Date
January 20, 2014
Gynaecological follow-up
Subjects received a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to four years in this gynaecological follow-up study (HPV-052 EXT 008). No vaccine was administered in this extension study. Subjects received 3 doses of Cervarix/Havrix vaccine, administered intramuscularly, according to a 0, 1, 6-month vaccination schedule in the HPV-008 (NCT00122681) primary study.
GSK Investigational Site, Taipei
GSK Investigational Site, Taipei
GSK Investigational Site, Taipei
GSK Investigational Site, Manila
GSK Investigational Site, Brussels
GSK Investigational Site, Makati City
GSK Investigational Site, Westmead
GSK Investigational Site, Edegem
GSK Investigational Site, Leuven
GSK Investigational Site, Parkville
GSK Investigational Site, Carlton
GSK Investigational Site, Los Banos, Laguna
GSK Investigational Site, New York
GSK Investigational Site, Bangkok
GSK Investigational Site, Bangkok
GSK Investigational Site, Bangkok
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Lahti
GSK Investigational Site, Pleasant Hills
GSK Investigational Site, Erie
GSK Investigational Site, Erie
GSK Investigational Site, Philadelphia
GSK Investigational Site, Turku
GSK Investigational Site, Hamburg
GSK Investigational Site, Hamburg
GSK Investigational Site, Rauma
GSK Investigational Site, Chapel Hill
GSK Investigational Site, Madrid
GSK Investigational Site, Pori
GSK Investigational Site, New Bern
GSK Investigational Site, Móstoles/Madrid
GSK Investigational Site, Hanover
GSK Investigational Site, Tampere
GSK Investigational Site, Miami
GSK Investigational Site, Clearwater
GSK Investigational Site, Bardstown
GSK Investigational Site, Jyväskylä
GSK Investigational Site, Modena
GSK Investigational Site, Kouvola
GSK Investigational Site, Kotka
GSK Investigational Site, Mikkeli
GSK Investigational Site, Iowa City
GSK Investigational Site, Lappeenranta
GSK Investigational Site, Mainz
GSK Investigational Site, Seinäjoki
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Vaasa
GSK Investigational Site, Wichita
GSK Investigational Site, Omaha
GSK Investigational Site, Kuopio
GSK Investigational Site, Tulsa
GSK Investigational Site, Karlsruhe
GSK Investigational Site, Rheinstetten
GSK Investigational Site, Munich
GSK Investigational Site, Albuquerque
GSK Investigational Site, Ravensburg
GSK Investigational Site, Oulu
GSK Investigational Site, Honolulu
GSK Investigational Site, Würzburg
GSK Investigational Site, Portland
GSK Investigational Site, Wenatchee
GSK Investigational Site, Nordhausen
GSK Investigational Site, Hobart
GSK Investigational Site, Perth
GSK Investigational Site, Cavite
GSK Investigational Site, Laguna
GSK Investigational Site, Las Piñas
GSK Investigational Site, Porto Alegre
GSK Investigational Site, Campinas
GSK Investigational Site, Curitiba
GSK Investigational Site, Edmonton
GSK Investigational Site, Langley
GSK Investigational Site, Truro
GSK Investigational Site, Beauport
GSK Investigational Site, Montreal
GSK Investigational Site, Helsinki
GSK Investigational Site, Leipzig
GSK Investigational Site, Barcelona
GSK Investigational Site, L'Hospitalet de Llobregat
GSK Investigational Site, Aberdeen
GSK Investigational Site, London
GSK Investigational Site, Manchester
Lead Sponsor
GlaxoSmithKline
INDUSTRY